The document provides an overview of Biocon's financial and operational performance in FY2012, highlighting 16% revenue growth and margins of 27% and 16%. It discusses Biocon's focus on developing affordable biologics and biosimilars through strategic partnerships, as well as its leadership in the Indian insulin market. Biocon is committed to reducing therapy costs for chronic diseases through innovation and global access.
The document provides results and highlights from Biocon for fiscal year 2012. It discusses Biocon's 16% revenue growth to Rs. 2,148 crores and EBITDA and PAT margins of 27% and 16% respectively. It outlines Biocon's research and development efforts including positive results from a phase 3 clinical trial of Itolizumab for psoriasis. It also discusses Biocon's partnerships with Mylan for biosimilar monoclonal antibodies and its biosimilars portfolio including insulin products in clinical trials. The financial highlights section shows Q4 and full year 2012 results.
Innovative Science Affordable Medicine - JP Morgan_Biocon Health Conference J...Biocon
Biocon is an emerging global biopharmaceutical company focused on developing affordable products for patients worldwide. It presented on its research and product pipeline at the JP Morgan Healthcare Conference. It has a risk-balanced approach developing generics, biosimilars, novel molecules, and branded formulations. It is leveraging emerging markets which offer high growth opportunities, with 50% of its current revenues coming from emerging markets. Its product pipeline includes several biosimilars including insulin analogs, monoclonal antibodies, and novel molecules like Itolizumab which is in Phase III trials in India for the treatment of psoriasis.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India where it has the number 1 or 2 market share for several drugs. The presentation outlines Biocon's research and development efforts including its pipeline of novel molecules and biologics in diabetes, oncology and immunology. Key pipeline programs discussed are Itolizumab in Phase 3 for rheumatoid arthritis, IN-105 for oral insulin, and partnerships for strategic alliances.
Brett Begeman, Executive Vice President of International Commercial at Citigroup Investment Research, presented at the 16th Annual Investment Conference on December 7, 2005. The presentation included forward-looking statements and defined non-GAAP financial measures. It provided an overview of Monsanto's two-step strategy to grow its current portfolio globally and lead through innovation. Monsanto sources the world's corn and soy needs, and acceleration in seeds and traits is driving commercial gross profit evolution.
The document discusses Hypermarcas, the largest consumer goods company in Brazil. It operates across multiple product categories including health and wellness, beauty and personal care, and home care and food. Hypermarcas pursues a growth strategy of profitable acquisitions, organic growth through relaunches and distribution improvements, and low-cost operations through economies of scale. The company's strengths are its leading brands, investments in advertising, product innovation, and efficient distribution network.
This report analyzes the worldwide markets for Soy Chemicals in US$ Million by the following End-use Segments: Plastics, Biodiesel, Food & Beverages, and Others. The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 66 companies including many key and niche players such as Ag Environmental Products, LLC, Archer Daniels Midland Company, BioBased Technologies
The document provides an investor presentation for Biocon from September 2011. It summarizes Biocon as an emerging global biopharmaceutical company focused on developing affordable therapies. It discusses Biocon's business structure, product portfolio across areas like diabetes, oncology and biosimilars. The presentation outlines Biocon's research and development pipeline including oral insulin and monoclonal antibody programs. It also describes Biocon's strategic partnerships with companies like Pfizer, Mylan, Amylin and others. Financial highlights show Biocon's revenues growing over 2008-2011 time period with contributions from areas like research services, branded formulations and biosimilars.
The document provides results and highlights from Biocon for fiscal year 2012. It discusses Biocon's 16% revenue growth to Rs. 2,148 crores and EBITDA and PAT margins of 27% and 16% respectively. It outlines Biocon's research and development efforts including positive results from a phase 3 clinical trial of Itolizumab for psoriasis. It also discusses Biocon's partnerships with Mylan for biosimilar monoclonal antibodies and its biosimilars portfolio including insulin products in clinical trials. The financial highlights section shows Q4 and full year 2012 results.
Innovative Science Affordable Medicine - JP Morgan_Biocon Health Conference J...Biocon
Biocon is an emerging global biopharmaceutical company focused on developing affordable products for patients worldwide. It presented on its research and product pipeline at the JP Morgan Healthcare Conference. It has a risk-balanced approach developing generics, biosimilars, novel molecules, and branded formulations. It is leveraging emerging markets which offer high growth opportunities, with 50% of its current revenues coming from emerging markets. Its product pipeline includes several biosimilars including insulin analogs, monoclonal antibodies, and novel molecules like Itolizumab which is in Phase III trials in India for the treatment of psoriasis.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India where it has the number 1 or 2 market share for several drugs. The presentation outlines Biocon's research and development efforts including its pipeline of novel molecules and biologics in diabetes, oncology and immunology. Key pipeline programs discussed are Itolizumab in Phase 3 for rheumatoid arthritis, IN-105 for oral insulin, and partnerships for strategic alliances.
Brett Begeman, Executive Vice President of International Commercial at Citigroup Investment Research, presented at the 16th Annual Investment Conference on December 7, 2005. The presentation included forward-looking statements and defined non-GAAP financial measures. It provided an overview of Monsanto's two-step strategy to grow its current portfolio globally and lead through innovation. Monsanto sources the world's corn and soy needs, and acceleration in seeds and traits is driving commercial gross profit evolution.
The document discusses Hypermarcas, the largest consumer goods company in Brazil. It operates across multiple product categories including health and wellness, beauty and personal care, and home care and food. Hypermarcas pursues a growth strategy of profitable acquisitions, organic growth through relaunches and distribution improvements, and low-cost operations through economies of scale. The company's strengths are its leading brands, investments in advertising, product innovation, and efficient distribution network.
This report analyzes the worldwide markets for Soy Chemicals in US$ Million by the following End-use Segments: Plastics, Biodiesel, Food & Beverages, and Others. The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 66 companies including many key and niche players such as Ag Environmental Products, LLC, Archer Daniels Midland Company, BioBased Technologies
The document provides an investor presentation for Biocon from September 2011. It summarizes Biocon as an emerging global biopharmaceutical company focused on developing affordable therapies. It discusses Biocon's business structure, product portfolio across areas like diabetes, oncology and biosimilars. The presentation outlines Biocon's research and development pipeline including oral insulin and monoclonal antibody programs. It also describes Biocon's strategic partnerships with companies like Pfizer, Mylan, Amylin and others. Financial highlights show Biocon's revenues growing over 2008-2011 time period with contributions from areas like research services, branded formulations and biosimilars.
The document provides an overview of Biocon's business including:
1) Biocon is an emerging global biopharmaceutical company focused on developing affordable therapies for chronic diseases like diabetes and cancer.
2) In FY2012, Biocon saw 16% revenue growth and a 27% EBITDA margin, initiated several clinical trials, and formed new strategic partnerships.
3) Biocon has a diversified portfolio spanning small molecules, branded formulations, biosimilars, and research services.
The document discusses Biocon, an Indian biopharmaceutical company. It summarizes Biocon's business structure and holdings, product portfolio including branded formulations, insulin business in India, and strategic partnerships. Notably, Biocon has entered a global commercialization partnership with Pfizer for biosimilar versions of insulin and insulin analogs, which provides upfront and milestone payments totaling $350 million to Biocon.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. In 3 sentences:
Biocon has a portfolio approach across small molecules, biosimilars, branded formulations and novel molecules. It has strategic partnerships for commercialization and research. Financial highlights showed steady revenue and profit growth over 2008-2011, with revenues reaching $402 million and net profit of $74 million in fiscal year 2011.
- Biocon is an emerging global biopharmaceutical company focused on developing affordable biologic drugs and biosimilars.
- It has several growth segments including small molecules, biosimilars, novel biologics, and research services.
- Biocon partners with other companies for drug development and commercialization to leverage its capabilities and for global access.
- In 9M FY13, Biocon saw revenue growth of 23% and EBITDA growth driven by performance across business segments.
Biocon reported financial results for the first half of FY13, with 23% revenue growth to INR 1235 crore. Key business segments grew substantially: Biopharma was up 15% to INR 734 crore, Branded Formulations increased 45% to INR 178 crore, and Research Services rose 40% to INR 252 crore. Biocon also made progress in areas like the global Phase 3 trial of its biosimilar insulin, a private equity investment in Syngene, and recognition as a top global employer in the biopharma sector. The company aims to achieve over $1 billion in revenue by FY18 through its five growth drivers.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company based in India. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India, research and development pipeline including potential new molecules and biosimilars. It also outlines strategic partnerships with Pfizer and Mylan to commercialize biosimilar insulins and monoclonal antibodies globally. Financial highlights show strong revenue and profit growth over the past years and in the first half of fiscal year 2012.
Biocon - Key updates and events
1. Biopharma posts robust revenue growth: 15% YoY
2. Statins: Strong growth in Q2; robust sales of Simvastatin and Pravastatin
3. Focus on improving operational efficiencies to augment capacities
4. Our biosimilar co-marketing Insulins partner, Pfizer has launched in the Indian markets.
Biocon provides an investor presentation summarizing its business operations and financial performance. It discusses its focus on developing biosimilars and biologics through research and development efforts. However, it notes that forward-looking statements in the presentation are subject to risks and uncertainties. The presentation provides an overview of Biocon's business segments and product portfolio, and highlights its financial results for the first quarter of the 2014 fiscal year which showed growth across key metrics.
1) The Chairman discussed Biocon's focus on developing affordable biopharmaceuticals to make healthcare more accessible globally through five growth verticals.
2) These verticals include small molecules, biosimilars, branded formulations, novel molecules, and integrated research services. Biosimilars and insulin formulations are seen as major growth opportunities.
3) Biocon is augmenting manufacturing, R&D, and marketing capabilities to pursue strong sustainable growth through a new facility in Malaysia and an R&D center in Bangalore. Clinical trials show promise for biosimilar molecules in development.
Biocon provides an investor presentation summarizing its business segments and financial performance. It operates in small molecules, biosimilars, branded formulations, research services, and novel molecules. Revenues have grown from $318 million in FY10 to $487 million in FY14. In Q1 FY15, revenues were $124 million. Biosimilars and research services represent key growth opportunities, while it continues developing a pipeline of novel molecules.
Biocon is an integrated biopharmaceutical company based in India with four business divisions: small molecules and enzymes, branded formulations, research services, and novel molecules. The document discusses Biocon's business overview, growth opportunities in key therapeutic areas like diabetes and oncology, strong partnerships with large pharmaceutical companies, and promising pipeline of novel drug candidates. Biocon has a diversified business model and revenues, and is well-positioned to benefit from the large and growing biopharma industry globally.
This partnership between Biocon and Pfizer will enable Biocon's insulin portfolio to have a global presence. Pfizer will have exclusive commercialization rights for Biocon's biosimilar versions of insulin and insulin analogs globally. Biocon will be responsible for clinical development, manufacturing, supply, and regulatory approvals. The agreement is expected to provide upfront and milestone payments totaling $350 million to Biocon. This partnership will help expand access to affordable treatment options for diabetes patients worldwide.
Biocon Press Conference FY13 Results - April 26, 2013 Biocon
Biocon reported strong financial results for FY13 with 18% revenue growth. Net profit increased 50% due to exceptional items. Key business segments like research services and branded formulations grew over 30%. The company expanded its partnership with Mylan to include development and commercialization of generic insulin analogs. Biocon is progressing several biosimilars programs and expanding globally. It aims to reach $1 billion in sales by 2018 by growing its key business verticals with a focus on emerging markets. The company also reported on its CSR initiatives in healthcare and education in India.
This document provides an overview of the global nutricosmetics industry. It analyzes market trends, drivers, barriers and regional analysis for the US, Japan, Europe and rest of world. It also profiles 59 leading companies in the industry and provides historical data and forecasts for market size until 2017. Key findings include that the market is growing due to health and wellness trends, and Asia Pacific is leading demand for beauty drinks. Regions like North America have more limited appeal currently for nutricosmetics.
Indeed, we have changed the paradigm. Take a look at how we performed in the past year and what were the major developments of the past year. Also, gain an understanding of how we intend to take Biocon to the next level.
This report analyzes the worldwide markets for Nutraceuticals in US$ Million by the following Product Groups/Segments: Dietary Supplements (Vitamins, Minerals, Herbals, Non-Herbals, & Others), and Functional Foods. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 295 companies including many key and niche players such as Archer Daniels Midland Company, Bactolac Pharmaceutical, Inc., BASF AG, BASF Human Nutrition, Bayer Healthcare AG, Bayer Consumer Care, Ceapro, Inc., GlaxoSmithKline Plc, Groupe Danone, Arkopharma Laboratories SA, Mead Johnson Nutritionals Inc., Natrol, Inc., Nestl
This report analyzes the worldwide markets for Specialty Enzymes in US$ Million by the following product segments - Specialty Medical Enzymes, Polymerases, Nucleases, and Other Specialty Enzymes. The specific end-use segments discussed are Pharmaceuticals & Diagnostics, and Research/Biotechnology. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 44 companies including many key and niche players such as Advanced Enzymes Technologies Limited, Amano Enzyme Inc., Aureozyme Inc., Biocon Ltd., Biozyme Laboratories Limited, Danisco A/S, Genencor International, Inc., Kinetic Biosystems, Inc., Maxygen Inc, Codexis Inc., Novozymes A/S, Seravac Biotech (Pty) Ltd, Specialty Enzymes & Biochemicals Co., and Verenium Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
- Biocon delivered 23% year-over-year revenue growth in the first half of FY2013, driven by growth across business verticals like biopharmaceuticals and branded formulations.
- Net profit grew 8% to Rs. 169 Crores compared to the same period last year, despite a 54% increase in research and development spending and higher costs.
- Interim results from a Phase III trial of Biocon's biosimilar rh-Insulin in Europe showed comparable efficacy and safety to the innovator product.
Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)Biocon
This document announces job openings for several positions at a location in Bangalore, India. It provides requirements for Fill Finish Production, Insulin Production, Engineering & Maintenance, and Instrumentation roles. All positions require experience in a pharmaceutical or healthcare setting and working in shifts. Candidates should bring documentation to an interview at a hotel in Indore, Madhya Pradesh.
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016Biocon
Walk-in drive at Aurangabad for positions in Fill finish Production, Fill finish Packing, Engineering & Maintenance, Instrumentation, Insulin Production and Packing inspection.
Date: Oct 23, Sunday (9AM-2PM)
Venue: The Salt, MGM-Sports Club & Stadium, Behind MGM Hospital, N-6 CIDCO, MGM Campus, Aurangabad, 431003
#Job #Recruitment #Biotechnology #Hiring
The document provides an overview of Biocon's business including:
1) Biocon is an emerging global biopharmaceutical company focused on developing affordable therapies for chronic diseases like diabetes and cancer.
2) In FY2012, Biocon saw 16% revenue growth and a 27% EBITDA margin, initiated several clinical trials, and formed new strategic partnerships.
3) Biocon has a diversified portfolio spanning small molecules, branded formulations, biosimilars, and research services.
The document discusses Biocon, an Indian biopharmaceutical company. It summarizes Biocon's business structure and holdings, product portfolio including branded formulations, insulin business in India, and strategic partnerships. Notably, Biocon has entered a global commercialization partnership with Pfizer for biosimilar versions of insulin and insulin analogs, which provides upfront and milestone payments totaling $350 million to Biocon.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. In 3 sentences:
Biocon has a portfolio approach across small molecules, biosimilars, branded formulations and novel molecules. It has strategic partnerships for commercialization and research. Financial highlights showed steady revenue and profit growth over 2008-2011, with revenues reaching $402 million and net profit of $74 million in fiscal year 2011.
- Biocon is an emerging global biopharmaceutical company focused on developing affordable biologic drugs and biosimilars.
- It has several growth segments including small molecules, biosimilars, novel biologics, and research services.
- Biocon partners with other companies for drug development and commercialization to leverage its capabilities and for global access.
- In 9M FY13, Biocon saw revenue growth of 23% and EBITDA growth driven by performance across business segments.
Biocon reported financial results for the first half of FY13, with 23% revenue growth to INR 1235 crore. Key business segments grew substantially: Biopharma was up 15% to INR 734 crore, Branded Formulations increased 45% to INR 178 crore, and Research Services rose 40% to INR 252 crore. Biocon also made progress in areas like the global Phase 3 trial of its biosimilar insulin, a private equity investment in Syngene, and recognition as a top global employer in the biopharma sector. The company aims to achieve over $1 billion in revenue by FY18 through its five growth drivers.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company based in India. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India, research and development pipeline including potential new molecules and biosimilars. It also outlines strategic partnerships with Pfizer and Mylan to commercialize biosimilar insulins and monoclonal antibodies globally. Financial highlights show strong revenue and profit growth over the past years and in the first half of fiscal year 2012.
Biocon - Key updates and events
1. Biopharma posts robust revenue growth: 15% YoY
2. Statins: Strong growth in Q2; robust sales of Simvastatin and Pravastatin
3. Focus on improving operational efficiencies to augment capacities
4. Our biosimilar co-marketing Insulins partner, Pfizer has launched in the Indian markets.
Biocon provides an investor presentation summarizing its business operations and financial performance. It discusses its focus on developing biosimilars and biologics through research and development efforts. However, it notes that forward-looking statements in the presentation are subject to risks and uncertainties. The presentation provides an overview of Biocon's business segments and product portfolio, and highlights its financial results for the first quarter of the 2014 fiscal year which showed growth across key metrics.
1) The Chairman discussed Biocon's focus on developing affordable biopharmaceuticals to make healthcare more accessible globally through five growth verticals.
2) These verticals include small molecules, biosimilars, branded formulations, novel molecules, and integrated research services. Biosimilars and insulin formulations are seen as major growth opportunities.
3) Biocon is augmenting manufacturing, R&D, and marketing capabilities to pursue strong sustainable growth through a new facility in Malaysia and an R&D center in Bangalore. Clinical trials show promise for biosimilar molecules in development.
Biocon provides an investor presentation summarizing its business segments and financial performance. It operates in small molecules, biosimilars, branded formulations, research services, and novel molecules. Revenues have grown from $318 million in FY10 to $487 million in FY14. In Q1 FY15, revenues were $124 million. Biosimilars and research services represent key growth opportunities, while it continues developing a pipeline of novel molecules.
Biocon is an integrated biopharmaceutical company based in India with four business divisions: small molecules and enzymes, branded formulations, research services, and novel molecules. The document discusses Biocon's business overview, growth opportunities in key therapeutic areas like diabetes and oncology, strong partnerships with large pharmaceutical companies, and promising pipeline of novel drug candidates. Biocon has a diversified business model and revenues, and is well-positioned to benefit from the large and growing biopharma industry globally.
This partnership between Biocon and Pfizer will enable Biocon's insulin portfolio to have a global presence. Pfizer will have exclusive commercialization rights for Biocon's biosimilar versions of insulin and insulin analogs globally. Biocon will be responsible for clinical development, manufacturing, supply, and regulatory approvals. The agreement is expected to provide upfront and milestone payments totaling $350 million to Biocon. This partnership will help expand access to affordable treatment options for diabetes patients worldwide.
Biocon Press Conference FY13 Results - April 26, 2013 Biocon
Biocon reported strong financial results for FY13 with 18% revenue growth. Net profit increased 50% due to exceptional items. Key business segments like research services and branded formulations grew over 30%. The company expanded its partnership with Mylan to include development and commercialization of generic insulin analogs. Biocon is progressing several biosimilars programs and expanding globally. It aims to reach $1 billion in sales by 2018 by growing its key business verticals with a focus on emerging markets. The company also reported on its CSR initiatives in healthcare and education in India.
This document provides an overview of the global nutricosmetics industry. It analyzes market trends, drivers, barriers and regional analysis for the US, Japan, Europe and rest of world. It also profiles 59 leading companies in the industry and provides historical data and forecasts for market size until 2017. Key findings include that the market is growing due to health and wellness trends, and Asia Pacific is leading demand for beauty drinks. Regions like North America have more limited appeal currently for nutricosmetics.
Indeed, we have changed the paradigm. Take a look at how we performed in the past year and what were the major developments of the past year. Also, gain an understanding of how we intend to take Biocon to the next level.
This report analyzes the worldwide markets for Nutraceuticals in US$ Million by the following Product Groups/Segments: Dietary Supplements (Vitamins, Minerals, Herbals, Non-Herbals, & Others), and Functional Foods. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 295 companies including many key and niche players such as Archer Daniels Midland Company, Bactolac Pharmaceutical, Inc., BASF AG, BASF Human Nutrition, Bayer Healthcare AG, Bayer Consumer Care, Ceapro, Inc., GlaxoSmithKline Plc, Groupe Danone, Arkopharma Laboratories SA, Mead Johnson Nutritionals Inc., Natrol, Inc., Nestl
This report analyzes the worldwide markets for Specialty Enzymes in US$ Million by the following product segments - Specialty Medical Enzymes, Polymerases, Nucleases, and Other Specialty Enzymes. The specific end-use segments discussed are Pharmaceuticals & Diagnostics, and Research/Biotechnology. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 44 companies including many key and niche players such as Advanced Enzymes Technologies Limited, Amano Enzyme Inc., Aureozyme Inc., Biocon Ltd., Biozyme Laboratories Limited, Danisco A/S, Genencor International, Inc., Kinetic Biosystems, Inc., Maxygen Inc, Codexis Inc., Novozymes A/S, Seravac Biotech (Pty) Ltd, Specialty Enzymes & Biochemicals Co., and Verenium Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
- Biocon delivered 23% year-over-year revenue growth in the first half of FY2013, driven by growth across business verticals like biopharmaceuticals and branded formulations.
- Net profit grew 8% to Rs. 169 Crores compared to the same period last year, despite a 54% increase in research and development spending and higher costs.
- Interim results from a Phase III trial of Biocon's biosimilar rh-Insulin in Europe showed comparable efficacy and safety to the innovator product.
Similar to Biocon Results Presentation April 2012 (20)
Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)Biocon
This document announces job openings for several positions at a location in Bangalore, India. It provides requirements for Fill Finish Production, Insulin Production, Engineering & Maintenance, and Instrumentation roles. All positions require experience in a pharmaceutical or healthcare setting and working in shifts. Candidates should bring documentation to an interview at a hotel in Indore, Madhya Pradesh.
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016Biocon
Walk-in drive at Aurangabad for positions in Fill finish Production, Fill finish Packing, Engineering & Maintenance, Instrumentation, Insulin Production and Packing inspection.
Date: Oct 23, Sunday (9AM-2PM)
Venue: The Salt, MGM-Sports Club & Stadium, Behind MGM Hospital, N-6 CIDCO, MGM Campus, Aurangabad, 431003
#Job #Recruitment #Biotechnology #Hiring
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016 Biocon
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Biocon Walk in Interviews at Hyderabad on May 22, 2016Biocon
This document provides information about a walk-in interview being held by Biocon Limited in Hyderabad for various positions at their API, Biosimilars, and Injectable facilities in Bangalore. The walk-in will take place on May 22nd, 2016 from 9:00AM to 2:00PM at the Hotel Sree Krishnaa Grand in Hyderabad. Candidates should bring the required documents and register online. A number of positions are listed along with their required qualifications and experience.
Biocon organizing walk-in interviews at VishakhapatnamBiocon
Biocon Walk In at Vishakhapatnam
Venue: -
Integral Institute of Advanced Management (IIAM)
Plot Not 10, Sector 7, MVP Colony, Visakhapatnam - 530 017.
Landmark: Near to CBI Office
Date: Sunday, 22nd May 2016. Time: 9:00AM- 02:00PM
Biocon organizing walk-in interviews at Don Bosco College, Margao, GoaBiocon
Biocon Limited is India's premier biopharma company focused on delivering affordable healthcare globally. It has evolved into an emerging global enterprise serving over 100 partners and customers in 100+ countries. Biocon is ranked #6 among the top 20 global biotech employers by Science Magazine in 2013.
Biocon is looking for experienced professionals for their injectable facilities in Bangalore. Positions include Junior Executive/Executive/Senior Executive/Assistant Manager in Production, Junior Executive/Executive/Senior Executive in Engineering & Maintenance, and Executive/Senior Executive in Validation & Compliance. Candidates should bring documents including photos, CVs, educational and work experience certificates to the walk-in on December 13, 2015 in Margao
Biocon Walkin Interviews Hyderabad 29th November 2015Biocon
All available positions are Bangalore based. This document contains details of the Walkin Interviews scheduled to be held in Hyderabad on the 29th of November, Sunday.Refer this document for available positions and mandatory documents including venue details. Interested candidates can register themselves by clicking here: http://bit.ly/1lNUQGG
New Candidate Registration & Application Process: Navigation from Biocon.comBiocon
To apply for a job at Biocon Ltd., candidates must first create a profile by registering with a username and password. They can then search for suitable jobs, select one, and complete the application in the applicant cockpit. Alternatively, candidates can log in if they already have a profile and search for jobs or continue building their profile before applying. The registration and application process is designed to help candidates create a profile and apply for jobs on the corporate website.
India's first Int'l Conference on Best Practices in Pharma Microbiology Biocon
This is the first time that Pharmig, an international Pharmaceutical Microbiology think tank based out of the UK is organizing a conference on the "Best Practices in Pharma Microbiology" for the first time in India. You can register
by sending an email to maxine@pharmig.org.uk. For booking a seat for the conference, please visit: http://bit.ly/1J4gtLh
Biocon Bio Waste Disposal Company Statement Biocon
This is the official company statement regarding the trucks carrying waste from Biocon to Terra Firma for disposal as per Pollution Control Board Norms
This document provides details about the available positions for the Biocon Walk In Interviews scheduled to be held on the 28th of June, 2015. Candidates who are unable to attend the Walk In Interviews, are required to register
themselves on the careers page: http://bit.ly/1TRkJ53
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...Biocon
Canara Bank, Biocon Foundation, and OTTET have formed a public-private partnership to strengthen healthcare delivery in Odisha, India. Under this partnership, Biocon Foundation and OTTET will set up electronic diagnostic facilities and e-Health centers at primary health centers in Odisha managed by local entrepreneurs provided financial assistance from Canara Bank. This model aims to improve access to quality healthcare for rural communities by providing diagnostics, telemedicine consultations, and maintaining electronic health records.
Biocon is India's premier biopharma company focused on delivering affordable healthcare globally. It has facilities in Bangalore looking to hire skilled professionals. Positions include production roles in MAbs, fill finish, fermentation, insulin and GPP requiring diplomas or degrees in engineering, chemistry or biotechnology with relevant experience. Other roles include instrumentation, R&D and engineering/maintenance. Candidates should bring documents to a walk-in on November 9th between 9am-4pm or apply online.
Psoriasis is a chronic skin condition caused by genetic and environmental factors. It is characterized by red, scaly patches on the skin. While there is no way to prevent psoriasis, patients can help prevent flare ups by maintaining a healthy lifestyle and avoiding triggers. Treatments range from topical creams and drugs to phototherapy and biological treatments. Biological treatments are very effective but also expensive, while other traditional systems like homeopathy and ayurveda may also help if the treatment is genuine.
World Polio Day is observed annually on October 24th to commemorate the birth of Dr. Jonas Salk, who developed the first polio vaccine. Polio is a highly infectious disease that primarily affects children under 5 and can cause paralysis. The number of polio cases has declined over 99% since 1988 due to a global effort to eradicate the disease through vaccination. India was once considered highly polio-affected but has been polio-free for two years due to a robust vaccination program. However, the risk of polio persists until Pakistan and Bangladesh are also polio-free.
The document provides tips for quitting tobacco use. It recommends making a plan to quit on a specific date and getting support. Withdrawal symptoms like cravings can occur for weeks after quitting. Nicotine replacements can help with cravings. Tips include avoiding places one used tobacco, keeping busy, and remembering the health benefits of quitting like reduced risk of heart attack and improved circulation and taste. It encourages trying again if the first attempt at quitting fails.
This document discusses avoiding heart attacks and strokes by protecting oneself. It describes several heart conditions including heart failure, which occurs when the heart cannot pump enough blood due to damage from prior heart attacks or other causes. Congenital heart disease refers to defects present at birth, while rheumatic heart disease results from untreated strep throat and damages heart valves over time. Preventing rheumatic fever through prompt antibiotic treatment of strep throat is the best way to avoid rheumatic heart disease.
"Does Foreign Direct Investment Negatively Affect Preservation of Culture in the Global South? Case Studies in Thailand and Cambodia."
Do elements of globalization, such as Foreign Direct Investment (FDI), negatively affect the ability of countries in the Global South to preserve their culture? This research aims to answer this question by employing a cross-sectional comparative case study analysis utilizing methods of difference. Thailand and Cambodia are compared as they are in the same region and have a similar culture. The metric of difference between Thailand and Cambodia is their ability to preserve their culture. This ability is operationalized by their respective attitudes towards FDI; Thailand imposes stringent regulations and limitations on FDI while Cambodia does not hesitate to accept most FDI and imposes fewer limitations. The evidence from this study suggests that FDI from globally influential countries with high gross domestic products (GDPs) (e.g. China, U.S.) challenges the ability of countries with lower GDPs (e.g. Cambodia) to protect their culture. Furthermore, the ability, or lack thereof, of the receiving countries to protect their culture is amplified by the existence and implementation of restrictive FDI policies imposed by their governments.
My study abroad in Bali, Indonesia, inspired this research topic as I noticed how globalization is changing the culture of its people. I learned their language and way of life which helped me understand the beauty and importance of cultural preservation. I believe we could all benefit from learning new perspectives as they could help us ideate solutions to contemporary issues and empathize with others.
In a tight labour market, job-seekers gain bargaining power and leverage it into greater job quality—at least, that’s the conventional wisdom.
Michael, LMIC Economist, presented findings that reveal a weakened relationship between labour market tightness and job quality indicators following the pandemic. Labour market tightness coincided with growth in real wages for only a portion of workers: those in low-wage jobs requiring little education. Several factors—including labour market composition, worker and employer behaviour, and labour market practices—have contributed to the absence of worker benefits. These will be investigated further in future work.
Financial Assets: Debit vs Equity Securities.pptxWrito-Finance
financial assets represent claim for future benefit or cash. Financial assets are formed by establishing contracts between participants. These financial assets are used for collection of huge amounts of money for business purposes.
Two major Types: Debt Securities and Equity Securities.
Debt Securities are Also known as fixed-income securities or instruments. The type of assets is formed by establishing contracts between investor and issuer of the asset.
• The first type of Debit securities is BONDS. Bonds are issued by corporations and government (both local and national government).
• The second important type of Debit security is NOTES. Apart from similarities associated with notes and bonds, notes have shorter term maturity.
• The 3rd important type of Debit security is TRESURY BILLS. These securities have short-term ranging from three months, six months, and one year. Issuer of such securities are governments.
• Above discussed debit securities are mostly issued by governments and corporations. CERTIFICATE OF DEPOSITS CDs are issued by Banks and Financial Institutions. Risk factor associated with CDs gets reduced when issued by reputable institutions or Banks.
Following are the risk attached with debt securities: Credit risk, interest rate risk and currency risk
There are no fixed maturity dates in such securities, and asset’s value is determined by company’s performance. There are two major types of equity securities: common stock and preferred stock.
Common Stock: These are simple equity securities and bear no complexities which the preferred stock bears. Holders of such securities or instrument have the voting rights when it comes to select the company’s board of director or the business decisions to be made.
Preferred Stock: Preferred stocks are sometime referred to as hybrid securities, because it contains elements of both debit security and equity security. Preferred stock confers ownership rights to security holder that is why it is equity instrument
<a href="https://www.writofinance.com/equity-securities-features-types-risk/" >Equity securities </a> as a whole is used for capital funding for companies. Companies have multiple expenses to cover. Potential growth of company is required in competitive market. So, these securities are used for capital generation, and then uses it for company’s growth.
Concluding remarks
Both are employed in business. Businesses are often established through debit securities, then what is the need for equity securities. Companies have to cover multiple expenses and expansion of business. They can also use equity instruments for repayment of debits. So, there are multiple uses for securities. As an investor, you need tools for analysis. Investment decisions are made by carefully analyzing the market. For better analysis of the stock market, investors often employ financial analysis of companies.
1. Elemental Economics - Introduction to mining.pdfNeal Brewster
After this first you should: Understand the nature of mining; have an awareness of the industry’s boundaries, corporate structure and size; appreciation the complex motivations and objectives of the industries’ various participants; know how mineral reserves are defined and estimated, and how they evolve over time.
Lecture slide titled Fraud Risk Mitigation, Webinar Lecture Delivered at the Society for West African Internal Audit Practitioners (SWAIAP) on Wednesday, November 8, 2023.
The Rise of Generative AI in Finance: Reshaping the Industry with Synthetic DataChampak Jhagmag
In this presentation, we will explore the rise of generative AI in finance and its potential to reshape the industry. We will discuss how generative AI can be used to develop new products, combat fraud, and revolutionize risk management. Finally, we will address some of the ethical considerations and challenges associated with this powerful technology.
^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Duba...mayaclinic18
Whatsapp (+971581248768) Buy Abortion Pills In Dubai/ Qatar/Kuwait/Doha/Abu Dhabi/Alain/RAK City/Satwa/Al Ain/Abortion Pills For Sale In Qatar, Doha. Abu az Zuluf. Abu Thaylah. Ad Dawhah al Jadidah. Al Arish, Al Bida ash Sharqiyah, Al Ghanim, Al Ghuwariyah, Qatari, Abu Dhabi, Dubai.. WHATSAPP +971)581248768 Abortion Pills / Cytotec Tablets Available in Dubai, Sharjah, Abudhabi, Ajman, Alain, Fujeira, Ras Al Khaima, Umm Al Quwain., UAE, buy cytotec in Dubai– Where I can buy abortion pills in Dubai,+971582071918where I can buy abortion pills in Abudhabi +971)581248768 , where I can buy abortion pills in Sharjah,+97158207191 8where I can buy abortion pills in Ajman, +971)581248768 where I can buy abortion pills in Umm al Quwain +971)581248768 , where I can buy abortion pills in Fujairah +971)581248768 , where I can buy abortion pills in Ras al Khaimah +971)581248768 , where I can buy abortion pills in Alain+971)581248768 , where I can buy abortion pills in UAE +971)581248768 we are providing cytotec 200mg abortion pill in dubai, uae.Medication abortion offers an alternative to Surgical Abortion for women in the early weeks of pregnancy. Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby...Donc Test
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting, 8th Canadian Edition by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Ebook Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Pdf Solution Manual For Financial Accounting 8th Canadian Edition Pdf Download Stuvia Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Financial Accounting 8th Canadian Edition Ebook Download Stuvia Financial Accounting 8th Canadian Edition Pdf Financial Accounting 8th Canadian Edition Pdf Download Stuvia
2. SAFE HARBOR
Certain statements in this release concerning our future growth prospects are forward-
looking statements, which are subject to a number of risks, uncertainties and
assumptions that could cause actual results to differ materially from those contemplated
in such forward-looking statements. Important factors that could cause actual results to
differ materially from our expectations include, amongst others general economic and
business conditions in India, our ability to successfully implement our strategy, our
research and development efforts, our growth and expansion plans and technological
changes, changes in the value of the Rupee and other currency changes, changes in the
Indian and international interest rates, change in laws and regulations that apply to the
Indian and global biotechnology and pharmaceuticals industries, increasing competition
in and the conditions of the Indian biotechnology and pharmaceuticals industries,
changes in political conditions in India and changes in the foreign exchange control
regulations in India. Neither our company, nor our directors, nor any of their respective
affiliates have any obligation to update or otherwise revise any statements reflecting
circumstances arising after this date or to reflect the occurrence of underlying events,
even if the underlying assumptions do not come to fruition.
2
5. INTRODUCTION
Biocon is an emerging, global Bio-pharmaceutical
enterprise, focused on innovation to develop affordable products
and services
for patients, partners and healthcare systems across the world.
Biocon is committed towards:
Reducing therapy costs of chronic diseases. (diabetes, cancer & auto-immune diseases)
Strategic Research and marketing partnerships that provide global access
Leveraging the India advantage to deliver high value, licensable R&D assets
5
6. FY12 HIGHLIGHTS
Financial Performance
• Group Revenue at Rs. 2,148 Crores (16% YoY growth)
• EBITDA and PAT Margin at 27% and 16% respectively
Research & Development
• Itolizumab 52-week study successfully meets primary & secondary endpoints
• Phase III trials commenced for Biosimilar Trastuzumab (Herceptin, Mylan alliance)
• Global biosimilar Insulin trials nearing completion
Strategic Alliances
• 20+ new partnerships initiated in Syngene, including big pharma
• Amicable conclusion of biosimilar Insulin partnership with Pfizer
6
7. MANAGING THE FUTURE
ANDAs & 505b2 filings
Small
Molecules
Newer markets;
Integrated Progressing to
offerings from Research Biosimilars
Devices
discovery to clinics Services (Biologics &
Growth Insulins)
Verticals
Greater Novel Branded Rapidly growing,
Molecules Formulations India-centric business
risk-reward
paradigm
EMERGING MARKETS FOCUS
EMERGING MARKETS FOCUS 7
9. SMALL MOLECULES & BIOSIMILARS
Small
Molecules
Biosimilar
MAbs
(Mylan)
Biosimilar
Insulins
9
10. BIOSIMILARS COMMERCIALIZATION PARTNER: MYLAN
Monoclonal Antibodies (MAbs)
Combines Biocon's R&D and manufacturing prowess of
biologics with Mylan’s regulatory & commercialization
capabilities in the US and Europe
Market Value of Portfolio in 2011: ~33 Bn USD
Exclusive collaboration for development and commercialization of
.
complex biosimilars.
Basket of Products with patent expiries 2015 onward
(Trastuzumab, Peg-filgrastim, Bevacizumab, Adalimumab, Eternacept)
Mylan and Biocon to share development and capital costs.
Mylan will have exclusive commercialization rights in the regulated markets;
profits to be shared
Biocon and Mylan to have co-exclusive commercialization rights in other markets.
10
11. INSULINS: GLOBAL OPPORTUNITY
Total 2011 Insulin Market: USD ~17 Bn
USD
13% ~17 Bn
rh insulin 23%
20%
17%
lispro
14% 43%
glargine detemir USD 4%
32% 9% ~15 Bn
glulisine
2%
aspart
23%
2010 rh Insulin Glargine Lispro Aspart Others 2011
Market Breakup by Molecule Growth Contribution by Molecule
Source: Estimates compiled from earnings releases of respective companies & IMS data 11
13. BRANDED FORMULATIONS: #1 Indian Insulin Company
Biocon’s ranking* Value Growth YoY* Biocon’s Volume
Market share*
Fastest growing Insulin company
#4 in overall insulin market
Biocon: 53% 40 IU Insulin: 11%
#3 in the 40 IU Insulin market Sanofi Aventis: 29% Glargine vials: 84%
#1 in the Glargine vial market Novo Nordisk: 25%
INSUPen® ease
Reusable delivery device based
on proprietary German
technology, capable of
delivering both InsugenTM &
BasalogTM launched in India
* : ORG IMS MAT Feb 2012
13
14. BRANDED FORMULATIONS : CARVING A NICHE
Affordability Index* INDIA PRODUCT RANKINGS#
Cardiology
Basalog: 40%
Myokinase 2
Insugen: 15%
Clotide 2
Bestor: 30% Oncotherapeutics
BioMAb EGFR 2
Statix: 25%
Abraxane 3
Advacan: 45% Immunotherapy
Tacrograf: 30% Psorid 1
Tbis 2
Evertor: 59%
Picon 2
BioMAb EGFR: 53%
Nephrology
Picon: 37% Tacrograf 2
Psorid: 26% Renodapt & Renodapt S 3
*: Compared to the top selling competitor brand;
#: ORG IMS Jan MAT 2012
14
15. RESEARCH PARTNERSHIPS : HIGH POTENTIAL PRODUCT PIPELINE
Product Therapeutic Area Drug Partner Discovery Preclinical Phase I Phase II Phase III Market
Diabetes IN 105
Oncology /
Itolizumab CIMAb #
Novel Molecules*
Inflammation /
Auto immune
Oncology Nimotuzumab CIMAb
Oncology Anti-CD 20 Vaccinex
Oncology Fusion Proteins IATRICa
Diabetes Peptide Hybrid Amylin
Oncology/
Biosimilars*
Other MAbs & Biosimilar
Biosimilar MAbs Mylan PEG- GCSF Trastuzumab
Immunology
Diabetes Insulin & Analogues rH Insulin, Glargine
Oncology Others GCSF, EPO
* Includes molecules from collaborative programs; # Phase 3 TREAT PLAQ study In India, Phase 2(b) globally 15
16. ANTI- CD6 MAB: ITOLIZUMAB
Drug Highlights
Targets CD6
CD6 is a type 1 cell membrane glycoprotein belonging to the scavenger receptor cysteine-rich
(SRCR) super family group B.
CD6 is predominantly expressed by T cells & a B cell subset.
CD6 binds ALCAM (activated leukocyte cell adhesion molecule) which is expressed on:
Activated T, cells, B cells & monocytes.
Skin fibroblasts, keratinocytes, rheumatoid arthritis synovium.
TREAT-PLAQ Study in Psoriasis
Total Patient Enrollment 223
Trial Duration 52 Weeks
Interim Data Presented* 28 Weeks
* 52-week clinical study report; the regulatory package is currently being prepared for submission to the authorities. Key data would
be shared in concurrence with the submission. 16
17. TREAT PLAQ STUDY: SUMMARY OF 28-WEEK INTERIM RESULTS
PRIMARY ENDPOINT Result*
Statistically significant patient cohort with ≥ PASI 75 Vs. placebo at 12 Weeks
SECONDARY ENDPOINTS
Significant Proportion of subjects achieving PASI 50 and PASI 90
Safety & Tolerability
Improvement in PGA scores
Considerable Proportion of subjects with PGA score of “clear” or “minimal”
PASI: Psoriasis Area Severity Index PGA: Physicians Global Assessment *p <0.05 17
18. TREAT PLAQ STUDY: EFFICACY RESULTS
Representative patient samples from each arm.
Week Baseline 12 Weeks 28 Weeks
Trial Arm
Induction
Dose Arm
Fixed Dose
Arm
Placebo Arm
18
19. BIOCON RESEARCH CENTRE
State-of-the-art Integrated Research & Development Centre
First-of-its kind in South east Asia
Venue for world-class research on
biologics
Spread across 200,000 sq. ft. with:
Molecular Biology Lab
Biologics Process Science Labs
Formulations Development Lab
Molecular Characterization Lab
Functional Bioassay Lab
Preclinical & Clinical Development Groups
19
20. RESEARCH SERVICES: VALUE-BASED POSITIONING
Integrated Model spanning discovery & early
development to late stage clinical studies
Component
Play
Large Portfolio of Offerings combining Chemistry &
Biologics expertise with cost advantage Cluster Play
Custom partnership models ranging from FTE based Integrated
to risk-reward models
Incubative
Clientele comprising of 100+ large and mid-size
pharma & biotech companies
20